11 results on '"Cristinelli C"'
Search Results
2. TERAPIA ENDOCAVITARIA DI SECONDA LINEA CON GEMCITABINA NELLA NEOPLASIA VESCICALE NON MUSCOLO INVASIVA RECIDIVA AD ALTO RISCHIO
- Author
-
Canossi, E, Cristinelli, C, Gandossi, C, Moroni, A, Finamanti, M, Zani, Danilo, COSCIANI CUNICO, Sergio, and Simeone, Claudio
- Published
- 2008
3. Patterns of metabolic response in patients receiving commercial CAR T-cells for relapsing/refractory aggressive B cells lymphoma.
- Author
-
Vercellino L, Betterki S, Blanc E, de Kerviler E, Cristinelli C, Merlet P, Thieblemont C, Meignin V, and Di Blasi R
- Abstract
CAR T-cells is an innovative treatment for relapsed/refractory aggressive B cell lymphomas, initially proposed as third line therapy and beyond, now allowed as soon as second-line treatment for patients with early relapse after first-line treatment. FDG PET/CT remains the modality of choice to evaluate response to this therapeutic strategy, to detect or confirm treatment failure and allow for salvage therapy if needed. Correct classification of patients regarding response is thus of the utmost importance. In many cases, metabolic response follows classical known patterns, and Deauville score and Lugano criteria yield accurate characterization of patient status. However, given its specific mode of action, it can result in delayed response or atypical patterns of response. We report here a few examples of response from our experience to illustrate the existence of tricky cases. These atypical cases require multidisciplinary management, with clinical, biological, imaging and pathological work-up., (© The Author(s) 2024. Published by Oxford University Press on behalf of the British Institute of Radiology. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
4. Molecular characterization of diffuse large B-cell lymphomas associated with hepatitis C virus infection.
- Author
-
Sciarra R, Merli M, Cristinelli C, Lucioni M, Zibellini S, Riboni R, Furlan D, Uccella S, Zerbi C, Bianchi B, Gotti M, Ferretti VV, Varraso C, Fraticelli S, Lazic T, Defrancesco I, Mora B, Libera L, Mazzacane A, Carpi F, Berliner M, Neri G, Rizzo E, De Paoli F, Sessa F, Passamonti F, Paulli M, and Arcaini L
- Subjects
- Humans, Male, Aged, Female, Middle Aged, Aged, 80 and over, Hepacivirus genetics, Adult, High-Throughput Nucleotide Sequencing, Lymphoma, Large B-Cell, Diffuse genetics, Lymphoma, Large B-Cell, Diffuse virology, Hepatitis C complications, Hepatitis C genetics, Mutation
- Abstract
Hepatitis C virus (HCV)-associated diffuse large B-cell lymphoma (DLBCL) displays peculiar clinicopathological characteristics, but its molecular landscape is not fully elucidated. In this study, we investigated the clinicopathological and molecular features of 54 patients with HCV-associated DLBCL. The median age was 71 years. An underlying marginal zone lymphoma component was detected in 14.8% of cases. FISH analysis showed rearrangements involving BCL6 in 50.9% of cases, MYC in 11.3% and BCL2 in 3.7%. Lymph2Cx-based assay was successful in 38 cases, recognizing 16 cases (42.1%) as ABC and 16 cases as GCB subtypes, while six resulted unclassified. ABC cases exhibited a higher lymphoma-related mortality (LRM). Next-generation sequencing analysis showed mutations in 158/184 evaluated genes. The most frequently mutated genes were KMT2D (42.6%), SETD1B (33.3%), RERE (29.4%), FAS and PIM1 (27.8%) and TBL1XR1 (25.9%). A mutation in the NOTCH pathway was detected in 25.9% of cases and was associated with worst LRM. Cluster analysis by LymphGen classified 29/54 cases within definite groups, including BN2 in 14 (48.2%), ST2 in seven (24.2%) and MCD and EZB in four each (13.8%). Overall, these results indicate a preferential marginal zone origin for a consistent subgroup of HCV-associated DLBCL cases and suggest potential implications for molecularly targeted therapies., (© 2024 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
5. Long-Term Follow-Up of the Response-Adapted Intergroup EORTC/LYSA/FIL H10 Trial for Localized Hodgkin Lymphoma.
- Author
-
Federico M, Fortpied C, Stepanishyna Y, Gotti M, van der Maazen R, Cristinelli C, Re A, Plattel W, Lazarovici J, Merli F, Specht L, Schiano de Colella JM, Hutchings M, Versari A, Edeline V, Stamatoulas A, Girinsky T, Ricardi U, Aleman B, Meulemans B, Tonino S, Raemaekers J, and André M
- Subjects
- Humans, Antineoplastic Combined Chemotherapy Protocols adverse effects, Bleomycin, Dacarbazine, Disease-Free Survival, Doxorubicin, Follow-Up Studies, Neoplasm Recurrence, Local drug therapy, Prednisone, Procarbazine adverse effects, Vinblastine, Vincristine, Hodgkin Disease diagnostic imaging, Hodgkin Disease drug therapy, Hodgkin Disease pathology
- Abstract
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. The primary analysis of the Early positron emission tomography (ePET) Response-Adapted Treatment in localized Hodgkin Lymphoma H10 Trial demonstrated that in ePET-negative patients, the risk of relapse increased when involved-node radiotherapy (INRT) was omitted and that in ePET-positive patients, switching from doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) to bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPPesc) significantly improved 5-year progression-free survival (PFS). Here, we report the final results of a preplanned analysis at a 10-year follow-up. In the favorable (F) ePET-negative group, the 10-year PFS rates were 98.8% versus 85.4% (hazard ratio [HR], 13.2; 95% CI, 3.1 to 55.8; P value for noninferiority = .9735; difference test P < .0001) in favor of ABVD + INRT; in the unfavorable (U) ePET-negative group, the 10-year PFS rates were 91.4% and 86.5% (HR, 1.52; 95% CI, 0.84 to 2.75; P value for noninferiority = .8577; difference test P = .1628). In ePET-positive patients, the difference in terms of PFS between standard ABVD and intensified BEACOPPesc was no longer statistically significant (HR, 0.67; 95% CI, 0.37 to 1.20; P = .1777). In conclusion, the present long-term analysis confirms that in ePET-negative patients, the omission of INRT is associated with lower 10-year PFS. Instead, in ePET-positive patients, no significant difference between standard and experimental arms emerged although intensification with BEACOPPesc was safe, with no increase in late adverse events, namely, second malignancies.
- Published
- 2024
- Full Text
- View/download PDF
6. T-Cells Subsets in Castleman Disease: Analysis of 28 Cases Including Unicentric, Multicentric and HHV8-Related Clinical Forms.
- Author
-
Fraticelli S, Lucioni M, Neri G, Marchiori D, Cristinelli C, Merli M, Monaco R, Borra T, Lazzaro A, Uccella S, Arcaini L, and Paulli M
- Subjects
- Humans, Lymph Nodes pathology, Antibodies, Monoclonal, T-Lymphocyte Subsets metabolism, Forkhead Transcription Factors, Castleman Disease, Herpesvirus 8, Human
- Abstract
Castleman disease (CD) is a rare lymphoproliferative disorder that includes various clinico-pathological subtypes. According to clinical course, CD is divided into unicentric CD (UCD) and multicentric CD (MCD). MCD is further distinguished based on the etiological driver in herpes virus-8-related MCD (that can occur in the setting of HIV); in MCD associated with POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes); and idiopathic MCD (iMCD). The latter can also be divided in iMCD-TAFRO (thrombocytopenia, anasarca, fever, myelofibrosis, organomegaly) and iMCD not otherwise specified. To date, CD pathogenesis is still uncertain, but CD may represent the histological and clinical result of heterogeneous pathomechanisms. Transcriptome investigations in CD lymph nodes have documented the expression and up-regulation of different cytokines; furthermore, few recent studies have shown alterations of different T-cell subsets in CD patients, suggesting a possible role of the nodal microenvironment in CD development. On this basis, our study aimed to investigate the distribution of T-cell subsets in the clinico-pathological spectrum of CD. We evaluated the CD4/CD8 ratio and the number of T-regulatory (T-reg) FOXP3+ cells in 28 CD cases. In total, 32% of cases showed a decreased CD4/CD8 ratio due to increased CD8+ T-cells, including both UCD, iMCD, and HHV8+ MCD cases. The T-reg subset analysis revealed a statistically significant ( p < 0.0001) lower mean number of FOXP3+ T-reg cells in CD cases when compared with non-specific reactive lymph nodes. We did not find statistically significant differences in T-reg numbers between the different CD subtypes. These findings may suggest that alterations in T-cell subpopulations that can lead to disruption of immune system control may contribute to the numerous changes in different cellular compartments that characterize CD.
- Published
- 2023
- Full Text
- View/download PDF
7. Role of Rituximab Addition to First-line Chemotherapy Regimens in Nodular Lymphocyte-predominant Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi.
- Author
-
Gotti M, Sciarra R, Pulsoni A, Merli F, Luminari S, Zerbi C, Trentin L, Re A, Rusconi C, Viviani S, Rossi A, Cocito F, Botto B, Meli E, Pinto A, Dogliotti I, Gini G, Puccini B, Ricci F, Nassi L, Fabbri A, Liberati AM, Merli M, Filippi AR, Bonfichi M, Zoboli V, Tartaglia G, Annechini G, D'Elia GM, Del Giudice I, Alvarez I, Visentin A, Pravato S, Dalceggio D, Pagani C, Ferrari S, Cristinelli C, Lazic T, Ferretti VV, Ricardi U, and Arcaini L
- Abstract
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare entity whose neoplastic cells retain a B-cell phenotype with expression of CD20. Radiotherapy is recommended for favorable stage IA disease while for other stages guidelines suggest therapeutic strategies similar to those used for classic HL. The role of rituximab, although quite widespread, is not completely elucidated. We retrospectively analyzed baseline characteristics of 308 consecutive patients with NLPHL diagnosed in 19 Italian centers from 2000 to 2018. With a median follow-up of 8.4 years (interquartile range: 4.5-12.4) for treated patients, median overall survival (OS) was not reached and estimated 5-year OS was 97.8% and 5-year progression-free survival (PFS) was 84.5%. Five-year cumulative incidence of histological transformation was 1.4%, 95% confidence interval (CI), 0.5%-3.8%. After adjusting for lymphocyte count, splenic involvement, bulky disease and B symptoms (fever, drenching night sweats, unintentional loss >10% of body weight within the preceding 6 months), patients with stage II or more showed superior PFS with immunochemotherapy in comparison to chemotherapy alone (hazard ratio = 0.4, 95% CI, 0.2-0.8; P = 0.015). Our data suggest an advantage of the use of rituximab combined with chemotherapy ± radiotherapy in the treatment of stage II-III-IV NLPHL., Competing Interests: LA received advisory honoraria from Roche, Celgene, Janssen-Cilag, Verastem, Eusa Pharma, and Incyte, research support from Gilead, and travel expenses from Roche, Celgene, Janssen-Cilag, and Eusa Pharma, speakers bureau from Novartis. AP declares honoraria from Roche. All the other authors have no conflicts of interest to disclose., (Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.)
- Published
- 2023
- Full Text
- View/download PDF
8. Systematic screening for SARS-CoV-2 in patients with hematological malignancies on active anticancer treatment in the outpatient setting.
- Author
-
Varettoni M, Mangiacavalli S, Rattotti S, Cartia CS, Cavalloni C, Rossetti F, Ferretti VV, Bergamini F, Trotti C, Fiorelli N, Pagani G, Zerbi C, Ferrari J, Cristinelli C, Muzzi A, Marena C, Baldanti F, Bruno R, and Arcaini L
- Subjects
- Humans, Outpatients, SARS-CoV-2, COVID-19, Hematologic Neoplasms diagnosis, Hematologic Neoplasms drug therapy, Hematologic Neoplasms epidemiology
- Published
- 2021
- Full Text
- View/download PDF
9. Prognostic impact of somatic mutations on time to first treatment: Results of targeted next-generation sequencing in 211 patients with early stage chronic lymphocytic leukemia.
- Author
-
Varettoni M, Orlandi E, Zibellini S, Rossi M, Gentile M, Flospergher E, Ferretti VV, Rizzo E, Della Porta MG, Rattotti S, Cavalloni C, Bergamini F, Cristinelli C, Fabbri N, Gallì A, and Arcaini L
- Subjects
- Cohort Studies, High-Throughput Nucleotide Sequencing, Humans, Leukemia, Lymphocytic, Chronic, B-Cell diagnosis, Prognosis, Leukemia, Lymphocytic, Chronic, B-Cell genetics, Mutation
- Published
- 2021
- Full Text
- View/download PDF
10. Mutational and immunogenetic landscape of HCV-associated B-cell lymphoproliferative disorders.
- Author
-
Defrancesco I, Visentini M, Zibellini S, Minafò YA, Rattotti S, Ferretti VV, Rizzo E, Varettoni M, Frigeni M, Pulsoni A, Casato M, Colantuono S, Rossi M, Candido C, Zerbi C, Bergamini F, Cristinelli C, Fabbri N, Merli M, Zuccaro V, Bruno R, Paulli M, and Arcaini L
- Subjects
- Cryoglobulinemia genetics, Cryoglobulinemia immunology, Cryoglobulinemia mortality, Cryoglobulinemia virology, Follow-Up Studies, Gene Rearrangement, B-Lymphocyte, Heavy Chain, Gene Rearrangement, B-Lymphocyte, Light Chain, Humans, Immunoglobulin Variable Region genetics, Kaplan-Meier Estimate, Lymphoma, B-Cell genetics, Lymphoma, B-Cell immunology, Lymphoma, B-Cell mortality, Lymphoma, B-Cell virology, Lymphoproliferative Disorders genetics, Lymphoproliferative Disorders immunology, Lymphoproliferative Disorders mortality, Mutation, Neoplasm Proteins genetics, Progression-Free Survival, B-Lymphocytes chemistry, Hepacivirus pathogenicity, Hepatitis C complications, Lymphoproliferative Disorders virology
- Published
- 2021
- Full Text
- View/download PDF
11. Targeted next-generation sequencing reveals molecular heterogeneity in non-chronic lymphocytic leukemia clonal B-cell lymphocytosis.
- Author
-
Defrancesco I, Zibellini S, Boveri E, Frigeni M, Ferretti VV, Rizzo E, Bonometti A, Capuano F, Candido C, Rattotti S, Tenore A, Picone C, Flospergher E, Zerbi C, Bergamini F, Fabbri N, Cristinelli C, Varettoni M, Paulli M, and Arcaini L
- Subjects
- Aged, Alleles, Disease Susceptibility, Female, Gene Expression, Genetic Predisposition to Disease, Humans, Immunoglobulin Heavy Chains genetics, Immunohistochemistry, Immunophenotyping, Leukemia, Lymphocytic, Chronic, B-Cell metabolism, Male, Middle Aged, Mutation, Biomarkers, Tumor, Genetic Heterogeneity, High-Throughput Nucleotide Sequencing, Leukemia, Lymphocytic, Chronic, B-Cell diagnosis, Leukemia, Lymphocytic, Chronic, B-Cell genetics
- Abstract
Non-chronic lymphocytic leukemia (non-CLL) clonal B-cell lymphocytosis (CBL) encompasses a heterogeneous group of hematologic disorders that are still poorly understood. To shed light on their biological aspects, we retrospectively analyzed a highly selected series of 28 patients, who had a clonal B-cell population in the peripheral blood and in the bone marrow, without evidence of lymphoma. Extended targeted next-generation sequencing revealed wide molecular heterogeneity with MYD88 (14%), PDE4DIP (14%), BIRC3 (11%), CCND3 (11%), NOTCH1 (11%), and TNFAIP3 (11%) as the most mutated genes. Mutations of MYD88 were "nonclassic" in most cases. Although some genetic lesions were overlapping with indolent lymphomas, mainly splenic B-cell lymphomas of marginal zone origin and splenic diffuse red pulp small B-cell lymphoma, the genetic profile of our non-CLL CBL series seemed to suggest that various pathways could be involved in the pathogenesis of these disorders, not mirroring any specific lymphoma entity. These data better enlighten the molecular characteristics of non-CLL CBL; however, more efforts are needed in order to improve the diagnostic process, prognostication, and clinical management., (© 2020 John Wiley & Sons Ltd.)
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.